Plain-English fact sheet
Lixisenatide
Also known as Adlyxin, Lyxumia, lixisenatide acetate
Lixisenatide was approved in the United States for type 2 diabetes, but the Adlyxin products are listed as discontinued. A Phase 2 Parkinson study showed a motor signal with frequent gastrointestinal effects, not an approved neurologic use.
Quick answer
Lixisenatide is not FDA approved for Parkinson disease or neuroprotection. Its former U.S. Adlyxin products were approved for type 2 diabetes and are listed by FDA as discontinued; a small Phase 2 Parkinson trial needs larger confirmation.
By the PeptideFactSheets Editorial Team. Claims are source-checked under our editorial policy; clinician review is identified only when a named reviewer is shown.
What is Lixisenatide?
Lixisenatide is a peptide GLP-1 receptor agonist developed for glucose control in type 2 diabetes.
Interest in Parkinson disease comes from possible brain and inflammatory effects of GLP-1 signaling, not from the former diabetes approval.
Why are people interested in it?
The LIXIPARK trial reported less worsening on a motor score than placebo after one year.
That signal contrasts with a negative Phase 3 exenatide trial and makes replication, molecule differences, and study design especially important.
Current regulatory status
FDA records list the U.S. Adlyxin presentations as discontinued. The prior approval covered glycemic control in adults with type 2 diabetes, not Parkinson disease.
What is it approved for?
No FDA-approved use. This matters because clinical-trial participation and products marketed online are not the same as an approved medicine.
What is it being studied for?
Investigational areas
- Parkinson disease progression and neuroprotection
Evidence snapshot
Diabetes efficacy was sufficient for the former approval. Parkinson evidence is limited to a relatively small Phase 2 trial with a motor-score signal, substantial gastrointestinal adverse effects, and no proof of disease modification.
Potential benefits being researched
- LIXIPARK found less average worsening on the primary motor score than placebo over the controlled period.
- The study was not large enough to establish routine treatment, long-term disease modification, or broad class efficacy.
Potential does not mean proven. Study design, population, endpoint, and regulatory review matter.
Known or possible risks
- Nausea and vomiting were frequent in the Parkinson trial and affected tolerability.
- The former diabetes label described pancreatitis, severe gastrointestinal reactions, kidney injury, hypoglycemia in some combinations, and hypersensitivity risks.
- A discontinued commercial product and an investigational neurologic use create distinct access and evidence questions.
What we still do not know
- Whether a larger confirmatory Parkinson trial will reproduce the motor signal
- Whether the effect is symptomatic or disease modifying
- Longer-term neurologic outcomes and tolerability
- Why lixisenatide and exenatide trials produced different results
Plain-English takeaway
Lixisenatide offers a real Parkinson research signal, but not an approved neurologic treatment. The discontinued U.S. product, small trial, and tolerability burden all matter.
Research and reference links
Use these primary and reputable sources to verify status and read beyond this summary. Trial registries may list studies without proving a benefit.
- 1FDA Purple Book: Adlyxin product status
FDA record showing original approval details and discontinued marketing status.
- 2FDA prescribing information: Adlyxin
Former diabetes indication, warnings, adverse reactions, and clinical evidence.
- 3LIXIPARK randomized Phase 2 trial
Controlled early-Parkinson study reporting a motor-score signal and gastrointestinal adverse effects.